Adcock Remains Resilient In Tough Business Environment
Firm Has Discontinued Three Generic Products This Year
Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.
You may also be interested in...
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.
Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.